SG11201609370QA - T cell-redirected antigen-binding molecule for cells having immunosuppression function - Google Patents

T cell-redirected antigen-binding molecule for cells having immunosuppression function

Info

Publication number
SG11201609370QA
SG11201609370QA SG11201609370QA SG11201609370QA SG11201609370QA SG 11201609370Q A SG11201609370Q A SG 11201609370QA SG 11201609370Q A SG11201609370Q A SG 11201609370QA SG 11201609370Q A SG11201609370Q A SG 11201609370QA SG 11201609370Q A SG11201609370Q A SG 11201609370QA
Authority
SG
Singapore
Prior art keywords
cells
cell
binding molecule
redirected
antigen
Prior art date
Application number
SG11201609370QA
Inventor
Tomoyuki Igawa
Takahiro Ishiguro
Shimon Sakaguchi
Hiroyoshi Nishikawa
Original Assignee
Chugai Pharmaceutical Co Ltd
Univ Osaka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd, Univ Osaka filed Critical Chugai Pharmaceutical Co Ltd
Publication of SG11201609370QA publication Critical patent/SG11201609370QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
SG11201609370QA 2014-05-13 2015-05-13 T cell-redirected antigen-binding molecule for cells having immunosuppression function SG11201609370QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014099707 2014-05-13
PCT/JP2015/063716 WO2015174439A1 (en) 2014-05-13 2015-05-13 T cell-redirected antigen-binding molecule for cells having immunosuppression function

Publications (1)

Publication Number Publication Date
SG11201609370QA true SG11201609370QA (en) 2016-12-29

Family

ID=54479976

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201609370QA SG11201609370QA (en) 2014-05-13 2015-05-13 T cell-redirected antigen-binding molecule for cells having immunosuppression function

Country Status (14)

Country Link
US (1) US11505605B2 (en)
EP (1) EP3144388B1 (en)
JP (1) JP6894702B2 (en)
KR (1) KR20170017916A (en)
CN (1) CN106459954A (en)
AU (1) AU2015260230A1 (en)
BR (1) BR112016026299A2 (en)
CA (1) CA2947157A1 (en)
EA (1) EA201692287A1 (en)
IL (1) IL248398A0 (en)
MX (1) MX2016014434A (en)
SG (1) SG11201609370QA (en)
TW (1) TW201623333A (en)
WO (1) WO2015174439A1 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
ES2568436T3 (en) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedure to control the blood pharmacokinetics of antibodies
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
BR112013013311A2 (en) 2010-11-30 2017-09-19 Chugai Pharmaceutical Co Ltd cytotoxicity-inducing therapeutic agent
WO2013147606A1 (en) 2012-03-28 2013-10-03 Umc Utrecht Holding B.V. Combinatorial gamma 9 delta 2 t cell receptor chain exchange
KR102441231B1 (en) 2013-09-27 2022-09-06 추가이 세이야쿠 가부시키가이샤 Method for producing polypeptide heteromultimer
TWI726842B (en) 2014-04-07 2021-05-11 日商中外製藥股份有限公司 Immune activation antigen binding molecule
MX2016014434A (en) 2014-05-13 2017-02-23 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function.
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
CA2978942A1 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
KR20180015650A (en) 2015-05-07 2018-02-13 아게누스 인코포레이티드 Anti-OX40 antibodies and methods of use thereof
EP3322732A2 (en) 2015-07-13 2018-05-23 Cytomx Therapeutics Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
US20190255107A1 (en) * 2015-10-09 2019-08-22 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
JP6931329B2 (en) * 2015-11-18 2021-09-01 中外製薬株式会社 Combination therapy using T cell redirection antigen-binding molecule for cells with immunosuppressive function
JP6925278B2 (en) * 2015-11-18 2021-08-25 中外製薬株式会社 Method of enhancing humoral immune response
CA3007233A1 (en) * 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
AU2017233658B2 (en) 2016-03-14 2023-09-21 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
MY196747A (en) * 2016-03-14 2023-05-03 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy
SG11201810023QA (en) 2016-05-27 2018-12-28 Agenus Inc Anti-tim-3 antibodies and methods of use thereof
CN109997041B (en) * 2016-06-10 2022-10-28 歌德塔有限公司 Human leukocyte antigen-restricted gamma delta T cell receptors and methods of use thereof
CN117586403A (en) 2016-10-11 2024-02-23 艾吉纳斯公司 anti-LAG-3 antibodies and methods of use thereof
MA46770A (en) 2016-11-09 2019-09-18 Agenus Inc ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
EP3575319A4 (en) * 2016-12-30 2021-03-10 Shanghai Sinobio Biotech Co., Ltd. Bifunctional molecule and use thereof
RU2725811C1 (en) * 2017-01-06 2020-07-06 Ютайлекс Ко., Лтд. Anti-human 4-1bb antibodies and use thereof
JPWO2018155611A1 (en) 2017-02-24 2019-12-12 中外製薬株式会社 Pharmaceutical composition, antigen binding molecule, therapeutic method, and screening method
SG11201907867TA (en) * 2017-02-28 2019-09-27 Bristol Myers Squibb Co Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
ES2776926T3 (en) * 2017-03-29 2020-08-03 Shionogi & Co Medicinal composition for cancer treatment
EP3618863B1 (en) 2017-05-01 2023-07-26 Agenus Inc. Anti-tigit antibodies and methods of use thereof
EP3630842A2 (en) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
BR112019021847A2 (en) 2017-05-30 2020-06-02 Bristol-Myers Squibb Company COMPOSITIONS UNDERSTANDING AN ANTI-LAG-3 ANTIBODY OR ANTI-LAG-3 ANTIBODY AND AN ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY
SI3631454T1 (en) 2017-05-30 2023-12-29 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
CN107099603A (en) * 2017-05-31 2017-08-29 成都克里斯博生物科技有限公司 Tumour immunity T cell detection kit and detection method
WO2018222949A1 (en) 2017-06-01 2018-12-06 Cytomx Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
EP3689909A4 (en) 2017-09-29 2021-12-29 Jiangsu Hengrui Medicine Co., Ltd. Tigit antibody, antigen-binding fragment thereof, and medical use thereof
GB201719169D0 (en) 2017-11-20 2018-01-03 Univ College Cardiff Consultants Ltd Novel T-cell receptor and ligand
CN112739371A (en) 2018-07-26 2021-04-30 百时美施贵宝公司 LAG-3 combination therapy for the treatment of cancer
SG11202102864XA (en) 2018-10-19 2021-05-28 Bristol Myers Squibb Co Combination therapy for melanoma
US20220089770A1 (en) * 2019-01-24 2022-03-24 Chugai Seiyaku Kabushiki Kaisha Novel cancer antigens and antibodies of said antigens
CN114127315A (en) 2019-05-30 2022-03-01 百时美施贵宝公司 Method of identifying subjects suitable for immunooncology (I-O) therapy
EP3976831A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
KR20220017430A (en) * 2019-06-05 2022-02-11 추가이 세이야쿠 가부시키가이샤 Antibody Cleavage Site Binding Molecules
EP3984554A4 (en) * 2019-06-11 2023-11-08 ONO Pharmaceutical Co., Ltd. Immunosuppression agent
BR112021023173A2 (en) * 2019-07-10 2022-01-04 Chugai Pharmaceutical Co Ltd Claudin-6 binding molecules and uses thereof
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CA3153777A1 (en) 2019-09-22 2021-03-25 Bristol-Myers Squibb Company Quantitative spatial profiling for lag-3 antagonist therapy
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
CA3160479A1 (en) 2019-11-08 2021-05-14 Bristol-Myers Squibb Company Lag-3 antagonist therapy for melanoma
JP2023514152A (en) 2020-02-06 2023-04-05 ブリストル－マイヤーズ スクイブ カンパニー IL-10 and its uses
EP4119162A4 (en) 2020-03-13 2023-08-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pvrig binding protein and its medical uses
KR20230035576A (en) 2020-07-07 2023-03-14 비온테크 에스이 RNA for the treatment of HPV-positive cancer
JP2023540255A (en) 2020-08-28 2023-09-22 ブリストル－マイヤーズ スクイブ カンパニー LAG-3 antagonist therapy for hepatocellular carcinoma
WO2022047412A1 (en) 2020-08-31 2022-03-03 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
CA3196496A1 (en) 2020-10-23 2022-04-28 Laurence David TOMS Lag-3 antagonist therapy for lung cancer
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
IL303648A (en) 2020-12-28 2023-08-01 Bristol Myers Squibb Co Antibody compositions and methods of use thereof
WO2022146948A1 (en) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
US20220267456A1 (en) * 2021-02-19 2022-08-25 Janssen Biotech, Inc. Materials and methods for targeting regulatory t cells for enhancing immune surveillance
KR20240005700A (en) 2021-03-29 2024-01-12 주노 쎄러퓨티크스 인코퍼레이티드 Dosing and Treatment Methods Using Combination of Checkpoint Inhibitor Therapy and CAR T Cell Therapy
TW202304965A (en) 2021-05-04 2023-02-01 美商艾吉納斯公司 Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof
EP4337694A1 (en) 2021-05-12 2024-03-20 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
KR20240046323A (en) 2021-07-13 2024-04-08 비온테크 에스이 Multispecific binding agent for CD40 and CD137 in combination therapy for cancer
CA3231553A1 (en) 2021-09-15 2023-03-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody
WO2023040945A1 (en) 2021-09-15 2023-03-23 江苏恒瑞医药股份有限公司 Protein specifically binding to pd-1 and pharmaceutical use thereof
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
WO2023077090A1 (en) 2021-10-29 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
WO2023147371A1 (en) 2022-01-26 2023-08-03 Bristol-Myers Squibb Company Combination therapy for hepatocellular carcinoma
WO2023164638A1 (en) 2022-02-25 2023-08-31 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
WO2023170606A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
CN115806629A (en) * 2022-08-03 2023-03-17 深圳市先康达生命科学有限公司 Autocrine IL-15 and anti-CTLA4 combined fusion protein and application thereof

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
DE69032484T4 (en) 1989-10-27 1999-09-16 Arch Dev Corp COMPOSITIONS AND THE USE THEREOF TO PROMOTE IMMUNOPOTENTIATION
US6025165A (en) 1991-11-25 2000-02-15 Enzon, Inc. Methods for producing multivalent antigen-binding proteins
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6805869B2 (en) 1996-06-12 2004-10-19 Shanghai Cp Guojian Pharmaceutical Co., Ltd. Cellular vaccines and immunotherapeutics and methods for their preparation
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO1999061057A2 (en) 1998-05-23 1999-12-02 Tanox, Inc. Molecules targeting cd40 and tumor cells
DE69911793T2 (en) 1998-07-28 2004-08-12 Micromet Ag HETERO MINI BODY
WO2000018806A1 (en) 1998-09-25 2000-04-06 Horst Lindhofer Bispecific and trispecific antibodies which specifically react with inducible surface antigens as operational target structures
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
ES2694002T3 (en) * 1999-01-15 2018-12-17 Genentech, Inc. Polypeptide comprising an Fc region of variant human IgG1
ATE286074T1 (en) * 1999-03-11 2005-01-15 Micromet Ag ANTIBODY CONSTRUCTS DIRECTED AGAINST CCR5 AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US20020103345A1 (en) 2000-05-24 2002-08-01 Zhenping Zhu Bispecific immunoglobulin-like antigen binding proteins and method of production
DE10034607A1 (en) 2000-07-20 2002-02-07 Gundram Jung Multi-specific reagent for the selective stimulation of cell surface receptors
JP2004508036A (en) * 2000-09-08 2004-03-18 マイクロメット　アーゲー Antibodies and / or chemokine constructs and their use in immune disorders
CN1294148C (en) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 Single-stranded cyctic trispecific antibody
WO2004003019A2 (en) 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
US20040018557A1 (en) 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
EP2330130B1 (en) 2002-10-17 2014-08-27 Genmab A/S Human monoclonal antibodies against CD20
ES2729974T3 (en) * 2003-01-23 2019-11-07 Ono Pharmaceutical Co Specific antibody of human PD-1 and CD3
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
RU2337107C2 (en) 2003-05-02 2008-10-27 Ксенкор, Инк. OPTIMIZED Fc-VERSIONS THAT HAVE ALTERED BINDING TO FcγR AND METHODS FOR THEIR PRODUCTION
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
CA2560742A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
BRPI0511782B8 (en) 2004-06-03 2021-05-25 Novimmune Sa anti-cd3 antibodies, use and method of production thereof, pharmaceutical composition, isolated nucleic acid molecule and vector
NZ579543A (en) 2004-07-09 2011-07-29 Chugai Pharmaceutical Co Ltd Anti-glypican 3 antibody
DK1776384T3 (en) 2004-08-04 2013-09-02 Mentrik Biotech Llc VARIANT Fc REGIONS
CA2595169A1 (en) 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
EP1820513A1 (en) * 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
ES2568436T3 (en) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedure to control the blood pharmacokinetics of antibodies
CA2653387A1 (en) 2006-06-06 2007-12-21 Tolerrx, Inc. Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
JP2009541275A (en) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス Production of bispecific antibodies
US8298801B2 (en) * 2006-07-17 2012-10-30 Quintessence Biosciences, Inc. Methods and compositions for the treatment of cancer
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
US8398956B2 (en) 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
JPWO2008090960A1 (en) 2007-01-24 2010-05-20 協和発酵キリン株式会社 Recombinant antibody composition that specifically binds to ganglioside GM2
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
ES2540854T3 (en) 2007-06-29 2015-07-14 Merck Sharp & Dohme Corp. Uses of MDL-1 antagonists
SG10201605394SA (en) 2007-09-26 2016-08-30 Chugai Pharmaceutical Co Ltd Modified Antibody Constant Region
EP2203180B1 (en) 2007-10-22 2012-11-21 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
ES2618292T3 (en) 2008-01-31 2017-06-21 Inserm - Institut National De La Sante Et De La Recherche Medicale Antibodies against and use of human CD39 to inhibit the activity of regulatory T cells
US8263073B2 (en) 2008-02-04 2012-09-11 Medarex, Inc. Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof
AU2009228158B2 (en) 2008-03-27 2014-02-27 Zymogenetics, Inc. Compositions and methods for inhibiting PDGFRbeta and VEGF-A
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
WO2010034441A1 (en) 2008-09-26 2010-04-01 F. Hoffmann-La Roche Ag Bispecific anti-egfr/anti-igf-1r antibodies
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
RU2547600C2 (en) * 2008-10-01 2015-04-10 Эмджен Рисерч (Мьюник) Гмбх Pscaxcd3, cd19xcd3, c-metxcd3, endosialin xcd3, epcamxcd3, igf-1rxcd3 or fap-alpha xcd3 bispecific single-chain antibody with inter-species specificity
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
DE202008016028U1 (en) 2008-12-04 2010-04-15 Melitta Haushaltsprodukte Gmbh & Co. Kg Containers for storing objects
US20120100140A1 (en) 2009-01-23 2012-04-26 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
PT3903829T (en) 2009-02-13 2023-06-02 Immunomedics Inc Immunoconjugates with an intracellularly-cleavable linkage
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
CN102471380B (en) 2009-04-01 2015-01-14 霍夫曼-拉罗奇有限公司 Anti-fcrh5 antibodies and immunoconjugates and methods of use
JP2012525149A (en) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド Method for making heteromultimeric molecules
RU2570633C2 (en) 2009-05-27 2015-12-10 Ф.Хоффманн-Ля Рош Аг Tri- or tetraspecific antibodies
PL2975051T3 (en) * 2009-06-26 2021-09-20 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
CA2773515C (en) 2009-09-29 2015-04-28 Roche Glycart Ag Bispecific death receptor agonistic antibodies
EP2490714A4 (en) 2009-10-20 2013-11-13 Glaxo Group Ltd Anti-cd3 antibody dosing in autoimmune disease
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
JP5889181B2 (en) 2010-03-04 2016-03-22 中外製薬株式会社 Antibody constant region variants
TWI653333B (en) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 Cross-species specific PSMAxCD3 bispecific single chain antibody
SG184427A1 (en) 2010-04-20 2012-11-29 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
RU2624027C2 (en) 2010-04-23 2017-06-30 Дженентек, Инк. Heteromultimeric proteins production
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
WO2011147986A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
EP2425997B1 (en) 2010-09-01 2013-04-24 Inalfa Roof Systems Group B.V. Roof assembly for a vehicle
JP6167040B2 (en) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Design of stable heterodimeric antibodies with mutations in the Fc domain
BR112013013311A2 (en) 2010-11-30 2017-09-19 Chugai Pharmaceutical Co Ltd cytotoxicity-inducing therapeutic agent
CN103347898B (en) 2011-01-10 2017-12-05 Ct大西洋有限公司 Including the therapeutic alliance with tumor associated antigen binding antibody
CA2827170A1 (en) 2011-02-11 2012-08-16 David M. Hilbert Monovalent and multivalent multispecific complexes and uses thereof
KR102147548B1 (en) 2011-02-25 2020-08-24 추가이 세이야쿠 가부시키가이샤 FcγRIIb-specific Fc antibody
EP2698431B1 (en) 2011-03-30 2020-09-09 Chugai Seiyaku Kabushiki Kaisha Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
WO2012145183A2 (en) 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
EP2537864B1 (en) 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
MX354922B (en) * 2011-06-30 2018-03-26 Genzyme Corp Inhibitors of t-cell activation.
US20130058937A1 (en) 2011-08-23 2013-03-07 Johannes Auer Bispecific antigen binding molecules
HUE038225T2 (en) 2011-08-23 2018-10-29 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
TR201904882T4 (en) 2011-11-17 2019-05-21 Gundram Jung Bispecific antibodies for medical use.
LT2794658T (en) 2011-12-19 2017-05-10 Synimmune Gmbh Bispecific antibody molecule
AU2013285355A1 (en) 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
EP3586874A1 (en) 2012-08-14 2020-01-01 IBC Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
JOP20200236A1 (en) 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
EP3508215A3 (en) * 2012-12-03 2019-10-02 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
WO2014138306A1 (en) * 2013-03-05 2014-09-12 Baylor College Of Medicine Engager cells for immunotherapy
AU2014232416B2 (en) 2013-03-15 2017-09-28 Xencor, Inc. Modulation of T Cells with Bispecific Antibodies and FC Fusions
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
WO2014165818A2 (en) 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions and methods for preventing and treating prostate cancer
KR20230073341A (en) 2013-07-05 2023-05-25 젠맵 에이/에스 Humanized or chimeric cd3 antibodies
KR102441231B1 (en) 2013-09-27 2022-09-06 추가이 세이야쿠 가부시키가이샤 Method for producing polypeptide heteromultimer
EP3176185A1 (en) * 2013-11-04 2017-06-07 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
PL3192812T3 (en) 2013-12-17 2020-10-19 Genentech, Inc. Anti-cd3 antibodies and methods of use
EP3096782A4 (en) 2014-01-21 2017-07-26 Medlmmune, LLC Compositions and methods for modulating and redirecting immune responses
AU2015220762B2 (en) 2014-02-21 2019-05-02 Cellectis Method for in situ inhibition of regulatory T cells
KR102497443B1 (en) * 2014-03-28 2023-02-08 젠코어 인코포레이티드 Bispecific antibodies that bind to cd38 and cd3
TWI726842B (en) 2014-04-07 2021-05-11 日商中外製藥股份有限公司 Immune activation antigen binding molecule
MX2016014434A (en) 2014-05-13 2017-02-23 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function.
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
WO2016194992A1 (en) 2015-06-05 2016-12-08 中外製薬株式会社 Combined use of immune activators
WO2017010423A1 (en) 2015-07-10 2017-01-19 中外製薬株式会社 Non-human animal having human cd3 gene substituted for endogenous cd3 gene
JP6931329B2 (en) 2015-11-18 2021-09-01 中外製薬株式会社 Combination therapy using T cell redirection antigen-binding molecule for cells with immunosuppressive function
JP6925278B2 (en) 2015-11-18 2021-08-25 中外製薬株式会社 Method of enhancing humoral immune response
AU2017233658B2 (en) 2016-03-14 2023-09-21 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
US20200123256A1 (en) 2017-05-02 2020-04-23 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
BR112020005834A2 (en) 2017-09-29 2020-09-24 Chugai Seiyaku Kabushiki Kaisha multispecific antigen binding molecule having blood clotting factor viii cofactor function (fviii) replacement activity, and pharmaceutical formulation containing said molecule as an active ingredient
US11667713B2 (en) 2017-12-28 2023-06-06 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
CA3100118A1 (en) 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
JP2022514262A (en) 2018-12-17 2022-02-10 レビトープ リミテッド Twin Immune Cell Engager

Also Published As

Publication number Publication date
JP6894702B2 (en) 2021-06-30
EP3144388A4 (en) 2018-05-02
TW201623333A (en) 2016-07-01
EA201692287A1 (en) 2017-06-30
JPWO2015174439A1 (en) 2017-04-20
BR112016026299A2 (en) 2018-02-20
US11505605B2 (en) 2022-11-22
WO2015174439A1 (en) 2015-11-19
EP3144388B1 (en) 2020-07-01
EP3144388A1 (en) 2017-03-22
CN106459954A (en) 2017-02-22
US20170260271A1 (en) 2017-09-14
MX2016014434A (en) 2017-02-23
KR20170017916A (en) 2017-02-15
AU2015260230A1 (en) 2016-11-17
IL248398A0 (en) 2016-11-30
CA2947157A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
IL248398A0 (en) T cell-redirected antigen-binding molecule for cells having immunosuppression function
IL274903A (en) Cell
ZA201901336B (en) Improved t cell compositions
IL263896A (en) T cell compositions for immunotherapy
IL247715A0 (en) Immunoactivating antigen-binding molecule
ZA201605660B (en) Multispecific antibodies
SI3131928T2 (en) Trifunctional antigen-binding molecule
PL3227332T3 (en) Multispecific antibodies
GB201414823D0 (en) Multispecific antibodies
ZA201700824B (en) Carrier molecule for antigens
HK1248555A1 (en) Selection methods for genetically-modified t cells
GB201421379D0 (en) Molecule
IL248936A0 (en) Small molecule lfa-1 inhibitors
EP3199491A4 (en) Recessed seam structure for cover
HUE042287T2 (en) Lithium-sulphur cell
GB201420069D0 (en) T cell recognised peptide epitopes
GB201410934D0 (en) T cell
GB201409759D0 (en) Molecule
GB201403479D0 (en) Molecule